Abstract
Introduction: Real-world(RW) clinical impact of mepolizumab in severe asthma is reported but few studies assessed sustained treatment benefits; the international REALITI-A study assessed longer-term outcomes.
Aims: To report key 2yr REALITI-A outcomes.
Methods: REALITI-A was a 2yr prospective, observational study enrolling pts with asthma, newly prescribed mepolizumab 100mg SC. Outcomes included the rate of clinically significant exacerbations (CSEs; requiring oral corticosteroids[OCS] and/or hospitalisation/emergency department[ED] visit) and exacerbations requiring hospitalisation/ED visits in 1yr pre- and 2yrs following mepolizumab initiation, and change in maintenance OCS (mOCS) use and dose in 28days prior (baseline) and Wks101–104 following mepolizumab initiation. Investigator-determined treatment-related adverse events(TRAEs) were collected.
Results: Patient demographics are shown in Table. By 2yrs, CSEs reduced by 74% and exacerbations requiring hospitalisation/ED visits reduced by 79% vs pre-treatment(Table). Furthermore, median mOCS dose reduced by 100% vs baseline(Table); 57%(95/168) of pts discontinued mOCS use. 599(73%) pts withdrew from/completed the study with mepolizumab treatment ongoing. TRAEs were observed in 90(11%) pts; 7(<1%) of these were serious, 1 fatal(hepatic cancer).
Conclusions: The 2yr REALITI-A data support long-term RW clinical benefits of mepolizumab in pts with severe asthma.
Funding: GSK(204710)
Footnotes
Cite this article as Eur Respir J 2022; 60: Suppl. 66, 4589.
This article was presented at the 2022 ERS International Congress, in session “-”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2022
